The use and precautions of pyrotinib/arini in special populations

Pyrotinib Maleate is contraindicated in pregnant women because animal experiments have shown embryotoxicity and may cause developmental disorders or severe malformations. Breastfeeding women need to stop breastfeeding as the drug may be secreted through breast milk. Women of childbearing age need to take effective contraceptive measures during treatment and within 8 weeks after stopping the drug, and avoid using estrogen-containing contraceptives. Elderly patients (≥65 years old) should use it with caution as it may increase the risk of liver function abnormalities or cardiovascular events. It is not recommended for people with moderate to severe hepatic insufficiency. Liver function needs to be monitored regularly during medication. If serious abnormalities occur, treatment must be discontinued. It is prohibited for children and adolescents under 18 years old to ensure the safety of medication for special groups.